Advanta VXT and Flixene PMCF Registry
Recruiting · NCT07161583
Conditions: Peripheral Arterial Disease
At a glance
- Research payments reported, 2025
- $15,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,000
About the trial
- Sponsor
- Atrium Medical Corporation
- Tested
- Advanta VXT Vascular Graft (device), Flixene Vascular Graft (device)
- Dates
- Started 2025-09-25; completion 2027-12
- Results posted
- Not yet
The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Atrium Medical Corporation reported $15,000 in research payments for this study in 2025 (1 payments).
Products named: Flixene
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.